Cite
HARVARD Citation
Blank, C. et al. (2017). Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. European journal of cancer. pp. 176-184. [Online].